<DOC>
	<DOCNO>NCT01266837</DOCNO>
	<brief_summary>A single arm , open-label , multi-center phase IV clinical trial patient metastatic renal cell carcinoma , progress first VEGF-targeted therapy .</brief_summary>
	<brief_title>Open Label , Single Arm Trial Characterize Patients With Metastatic RCC Treated With Everolimus After Failure First VEGF-targeted Therapy ( MARC-2 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Provide write informed consent 2 . Aged 18 year 3 . Histologically cytologically confirm predominantly clear cell renal cell carcinoma 4 . Metastatic disease document CT MRI ( histological confirmation mandatory wishful ) 5 . Patients without nephrectomy ( partial total ) 6 . Patients least one measurable lesion baseline accord RECIST criterion 1.1 7 . Failure exactly one prior VEGFRTKI therapy ( e.g . sunitinib , sorafenib , pazopanib ) metastatic renal cell carcinoma 8 . ECOG 02 9 . Hemoglobin ≥ 9.0 g/dL 10 . Platelet count ≥75,000/μL 11 . Absolute neutrophil count ≥1,5x109/l 12 . Serum creatinine &lt; 2.5 x ULN 13 . Liver function : Serum bilirubin ≤ 1.5 x ULN , AST ALT ≤ 2.5 x ULN . Patients suspect liver metastasis : AST ALT ≤ 5x ULN 14 . Able swallow study drug whole tablet 15 . Expected life expectancy least 6 month 16 . Women childbearing potential must negative serum pregnancy test within 14 day prior administration study treatment must document condition prohibits pregnancy ( e.g . hysterectomy , postmenopausal ) . 1 . Patients receive &gt; 1 prior VEGFRTKI therapy prior therapy bevacizumab +/ interferon . 2 . VEGFRTKI therapy within 14 day prior start study drug 3 . Patients previously receive systemic mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . 4 . Patients know hypersensitivity everolimus rapamycin ( sirolimus , temsirolimus ) excipients . 5 . Any condition , opinion investigator , would preclude participation trial 6 . Patients within 4 week postmajor surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) , open biopsy , significant traumatic injury avoid wound heal complication . Minor procedure percutaneous biopsy placement vascular access device require 7 day prior study entry . 7 . Patients radiation therapy within 4 week prior start study treatment . Palliative radiotherapy bone lesion within 2 week prior study treatment start . 8 . Patients anticipation need major surgical procedure course study . 9 . Patients serious nonhealing wound , ulcer , bone fracture . 10 . Patients history seizure ( ) control standard medical therapy . 11 . History clinical evidence central nervous system ( CNS ) metastases . Subjects previouslytreated CNS metastasis ( surgery ± radiotherapy , radiosurgery , gamma knife ) meet 3 follow criterion eligible : 1. asymptomatic , 2. evidence active CNS metastases ≥ 3 month prior enrolment ( inactive/controlled CNS metastasis allow ) , 3. requirement steroid enzymeinducing anticonvulsant ( e.g . carbamazepine , phenobarbital , phenytoin ) 12 . Patients receive chronic systemic treatment corticosteroid ( dose &gt; 10 mg/day methylprednisone equivalent ) another immunosuppressive agent . Inhaled topical steroid acceptable . 13 . Poorly control diabetes define fast serum glucose &gt; 2.0 x ULN . 14 . Impaired liver function classify ChildPugh class C. 15 . Active ( acute chronic ) uncontrolled infection bacterial , mycotic viral genesis . 16 . Liver disease chronic active hepatitis chronic persistent hepatitis . 17 . Patients known history HIV seropositivity . 18 . Patients active bleed disorder . 19 . Patients severe and/or uncontrolled medical condition condition within past 12 month could affect participation study cardiac angioplasty stenting , unstable angina pectoris , symptomatic peripheral vascular disease , symptomatic congestive heart failure ( NYHA II , III , IV ) , myocardial infarction ≤ 6 month prior first study treatment , serious uncontrolled cardiac arrhythmia , disorder impair ability evaluate patient patient complete study . 20 . Patients history another primary malignancy treatment ≤ 3 year , exception nonmelanoma skin cancer carcinoma situ uterine cervix breast , localized cancer bladder ( T1 ) prostate ( T1 T2 ) . 21 . Female patient pregnant breast feed . 22 . Men woman reproductive potential use highly effective birth control method . Oral contraceptive female patient barrier contraceptive acceptable . For definition highly effective birth control method please refer section 12.3.6 protocol . 23 . Patients use investigational agent receive investigational drug ≤ 2 week prior study treatment start . 24 . Patients unwilling unable comply protocol . 25 . Exclusion criterion MRI : intracorporal metal ( e.g . incompatible heart valve , pacemaker ) , contrast medium allergy , claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic renal cell carcinoma</keyword>
	<keyword>biomarker</keyword>
	<keyword>Everolimus</keyword>
</DOC>